Table 3.
Fibroblast growth factor 23 level at baseline and risk of incident CKD
| Model | n (Total) | n (Cases) | FGF23, pg/ml | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per 1 SD Increase of ln FGF23 | Quartile 1 (<31.9) | Quartile 2 (31.9–39.9) | Quartile 3 (40.0–50.2) | Quartile 4 (≥50.3) | ||||||||
| HR | 95% CI | P value | HR | 95% CI | HR | 95% CI | HR | 95% CI | ||||
| Unadjusted | 1110 | 644 | 1.26 | 1.11 to 1.43 | <0.001 | Reference | 1.08 | 0.78 to 1.50 | 1.47 | 1.06 to 2.03 | 1.81 | 1.33 to 2.48 |
| Adjusted for demographics | 1110 | 644 | 1.22 | 1.08 to 1.39 | 0.002 | Reference | 1.13 | 0.81 to 1.57 | 1.45 | 1.04 to 2.02 | 1.65 | 1.20 to 2.28 |
| Adjusted for demographics and eGFR | 1110 | 644 | 1.15 | 1.00 to 1.32 | 0.05 | Reference | 1.01 | 0.71 to 1.43 | 1.22 | 0.85 to 1.73 | 1.28 | 0.91 to 1.81 |
| Adjusted for demographics, eGFR, BP, smoking, diabetes duration, HbA1C, and BMI | 953 | 565 | 1.10 | 0.95 to 1.28 | 0.19 | Reference | 1.10 | 0.74 to 1.62 | 1.21 | 0.83 to 1.76 | 1.25 | 0.85 to 1.83 |
| Adjusted for demographics, eGFR, BP, smoking, diabetes duration, HbA1C, BMI, glycemic control arm, and ACEIs/ARBs | 953 | 565 | 1.11 | 0.95 to 1.28 | 0.18 | Reference | 1.07 | 0.73 to 1.59 | 1.20 | 0.82 to 1.76 | 1.25 | 0.85 to 1.82 |
| Adjusted for demographics, eGFR, BP, smoking, diabetes duration, HbA1C, BMI, glycemic control arm, ACEIs/ARBs, and serum phosphate | 953 | 565 | 1.09 | 0.94 to 1.27 | 0.25 | Reference | 1.06 | 0.72 to 1.57 | 1.18 | 0.81 to 1.73 | 1.20 | 0.81 to 1.76 |
HbA1C, hemoglovin A1C; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; HR, hazard ratio; ln, natural log; FGF23, fibroblast growth factor 23; 95% CI, 95% confidence interval.